Literature DB >> 21800074

Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Shotaro Iwamoto1, Takao Deguchi2, Hideaki Ohta3, Nobutaka Kiyokawa4, Masahito Tsurusawa5, Tomomi Yamada5, Kozo Takase6, Junichiro Fujimoto4, Ryoji Hanada7, Hiroki Hori2, Keizo Horibe8, Yoshihiro Komada2.   

Abstract

Although the antigen expression patterns of childhood acute lymphoblastic leukemia (ALL) are well known, little attention has been given to standardizing the diagnostic and classification criteria. We retrospectively analyzed the flow cytometric data from a large study of antigen expression in 1,774 children with newly diagnosed ALL in JPLSG. T- and B-lineage ALL accounted for 13 and 87% of childhood ALL cases, respectively. Cytoplasmic CD3 and CD7 antigens were positive in all T-ALL cases. More than 80% of T-ALL cases expressed CD2, CD5 and TdT. In B-lineage ALL, the frequencies of early pre-B, pre-B, transitional pre-B and B-ALL were 81, 15.5, 0.6 and 2.9%, respectively. More than 90% of early pre-B ALL cases expressed CD19, CD79a, CD22, CD10 and TdT. CD34 was expressed in three-fourths of early pre-B ALL cases. The frequencies of TdT and CD34 expression were lower in pre-B ALL than in early pre-B ALL. B-ALL showed less frequent expression of CD22, CD10, CD34 and TdT than other B-lineage ALL cases. Expression of CD13 and CD33, aberrant myeloid antigens, was significantly more frequently associated with B-lineage ALL than with T-ALL. Based on this retrospective study of antigen expression in 1,774 de novo childhood ALL cases in JPLSG, we propose standardized clinical guidelines for the immunophenotypic criteria for diagnosis and classification of pediatric ALL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800074     DOI: 10.1007/s12185-011-0900-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  30 in total

1.  Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study.

Authors:  F M Uckun; P S Gaynon; M G Sensel; J Nachman; M E Trigg; P G Steinherz; R Hutchinson; B C Bostrom; H N Sather; G H Reaman
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

2.  Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.

Authors:  M J Borowitz; J Shuster; A J Carroll; M Nash; A T Look; B Camitta; D Mahoney; S J Lauer; D J Pullen
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

3.  Immunophenotyping of leukemia.

Authors:  D Campana; F G Behm
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

4.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

Review 5.  Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia.

Authors:  C H Pui; F G Behm; W M Crist
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

Review 6.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

8.  Multiparameter characterization of L3 leukemia cell populations.

Authors:  A J Walle; A Al-Katib; G Y Wong; S C Jhanwar; R S Chaganti; B Koziner
Journal:  Leuk Res       Date:  1987       Impact factor: 3.156

9.  Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood.

Authors:  S R Wiersma; J Ortega; E Sobel; K I Weinberg
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

10.  Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Authors:  C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

View more
  11 in total

1.  Characterization of CD22 expression in acute lymphoblastic leukemia.

Authors:  Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne
Journal:  Pediatr Blood Cancer       Date:  2015-03-01       Impact factor: 3.167

2.  A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).

Authors:  Erica Brivio; Franco Locatelli; Marta Lopez-Yurda; Andrea Malone; Cristina Díaz-de-Heredia; Bella Bielorai; Claudia Rossig; Vincent H J van der Velden; Anneke C J Ammerlaan; Adriana Thano; Inge M van der Sluis; Monique L den Boer; Ying Chen; Barbara Sleight; Benoit Brethon; Karsten Nysom; Lucie Sramkova; Ingrid Øra; Luciana Vinti; Christiane Chen-Santel; Christian Michel Zwaan
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

3.  Adult T Lymphoblastic Leukemia (Pro-T ALL) with Reactive Monocytosis: A Case Report.

Authors:  Rachna Khera; Parul Gautam; Sanjeev Gupta; Prerna Arora; Tejinder Singh; Naresh Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-21       Impact factor: 0.900

4.  Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.

Authors:  Takeo Sarashina; Haruko Iwabuchi; Naoyuki Miyagawa; Masahiro Sekimizu; Tomoko Yokosuka; Kunio Fukuda; Satoshi Hamanoue; Fuminori Iwasaki; Shoko Goto; Masae Shiomi; Chihaya Imai; Hiroaki Goto
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

5.  Expression of myeloid antigens on lymphoblast surface in childhood acute lymphoblastic leukemia at diagnosis and its effect on early response to treatment: a preliminary report.

Authors:  Grazyna Sobol-Milejska; Agnieszka Mizia-Malarz; Halina Wos
Journal:  Int J Hematol       Date:  2013-07-24       Impact factor: 2.490

6.  Immunophenotypic characteristics of T lineage acute lymphoblastic leukemia: absence of immaturity markers-TdT, CD34 and HLADR is not uncommon.

Authors:  Richa Gupta; Neha Garg; Mrinalini Kotru; Dilip Kumar; Rajesh Pathak
Journal:  Am J Blood Res       Date:  2022-02-15

Review 7.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

Review 8.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

Review 9.  Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.

Authors:  Xinjie Xu; Shengkang Huang; Xinyi Xiao; Qihang Sun; Xiaoqian Liang; Sifei Chen; Zijing Zhao; Zhaochang Huo; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

10.  Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center.

Authors:  Karthik Bommannan; Jhansi Rani Arumugam; Venkatraman Radhakrishnan; Jayachandran Perumal Kalaiyarasi; Nikita Mehra; Tenali Gnana Sagar; Shirley Sundersingh
Journal:  Hematol Transfus Cell Ther       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.